Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation

Oechslin, Erwin; Kiowski, Wolfgang; Schneider, J.; Follath, F; Turina, M; Gallino, Augusto

doi:10.1093/oxfordjournals.annonc.a010499

Cited by 34 publications

(24 citation statements)

References 11 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[14] Recurrence rates from 0-33% have been recorded in the OHT literature, with all recurrences occurring in the first 5 years after transplantation. [1,2,[5][6][7][8]. Rates of recurrence in the LTx literature range from 0-57%, again with all recurrences occurring in the first 5 years after transplantation.…”

Section: Discussionmentioning

confidence: 99%

“…Perhaps this is due to the challenging nature of treating these systemic malignancies and the inherent difficulty in removing all disease burden. In the previously reported OHT literature, malignancy associated deaths occurred among patients with multiple tumor types including various adenocarcinomas, lymphomas, leukemias and cardiac sarcomas [5][6][7][8]. In a study by Koerner et al, 3 deaths (3/8[38%]) occurred in patients with histories of "plasmocytoma" [7].…”

Section: Discussionmentioning

confidence: 99%

“…The primary concern in these patients is the potential for recurrent, or de novo, malignancy due to the associated immunosuppression necessary to prevent allograft failure. [1][2][3][4][5][6][7][8][9] Currently, there is limited data on the impact of PTM on outcomes after lung transplantation(LTx) or orthotopic heart transplantation(OHT). The United Network for Organ Sharing(UNOS) database offers a unique opportunity to evaluate the impact of PTM on outcomes following LTx and OHT in a large modern cohort.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

384 Pre-Transplant Malignancy: An Analysis of Outcomes after Thoracic Organ Transplantation

Beaty¹,

George²,

Kilic³

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Purpose: Pre-transplant malignancy (PTM) is a relative contraindication to organ transplantation. Studies examining the impact of PTM on outcomes after lung transplantation (LTx) or orthotopic heart transplantation (OHT) are limited. We evaluated the impact of PTM on outcomes after LTx and OHT. Methods:We retrospectively reviewed primary adult LTx and OHT recipients in the United Network for Organ Sharing database. Primary and secondary stratification were by PTM and tumor type, respectively. Matched cohorts (2:1) as well as multivariable Cox proportional hazards regression models evaluated mortality.Results: From 2000-2011, 13,613 adults underwent LTx and 19,817 adults underwent OHT. 740 (5.4%) LTx patients and 1,117 (5.6%) OHT patients had PTM. On unadjusted analysis, both LTx patients and OHT patients with PTM had similar 30 day, 1-year and 5-year survivals (p>0.05) compared to no PTM. These findings persisted after risk-adjustment. No tumor types were associated with increased mortality in LTx patients. Patients with leukemia/lymphoma/myeloma (LLM) had a significant increase in univariate mortality at 30 days (HR:1.82, p=0.04), 1-year (HR:1.93, p<0.001) and 5-years (HR:1.54, p=0.01) in OHT patients. Matched cohort analysis revealed comparable outcomes in LTx patients, but confirmed increased univariate 1-year mortality (HR:1.89, p=0.006) in OHT patients with LLM. Conclusions:In the largest study evaluating the effects of PTM on LTx and OHT, the incidence of PTM is 5.4% and 5.6%, respectively. In general, PTM does not increase mortality in either cohort. However, OHT patients with LLM have an increased hazard of mortality. Therefore, carefully selected patients with PTM should not be excluded from LTx or OHT.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

384 Pre-Transplant Malignancy: An Analysis of Outcomes after Thoracic Organ Transplantation

Beaty¹,

George²,

Kilic³

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

show abstract

“…16%. Das Langzeitüberleben der Patienten wird in erster Linie durch akute und chronische Abstossungen, Infektionen sowie Begleiterkrankungen wie Lymphome und Karzinome bestimmt [15][16][17][18][19][20][21][22]. …”

Section: Verlauf Nach Herztransplantationunclassified

Die Herztransplantation in der Schweiz 1969-2003

Reho¹,

Noll

Ruschitzka³

et al. 2005

Schweiz Ärzteztg

View full text Add to dashboard Cite

“…[7][8][9][10] According to the International Society of Heart and Lung Transplant, the cumulative prevalence of malignancy in heart transplant patients at 1 year is 2.9% and at 10 years is 31.9%. Skin cancers and posttransplant lymphoproliferative disorder are the two most common malignancies shown in adults, 11 whereas lymphoma is the only reported cancer in pediatric patients, with a likelihood of occurrence of 8% at 10 years after transplant. 12 Here, the different types of cancers that occur in heart transplant patients are discussed to highlight their mechanisms and causes.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Lateef

Basit²,

Abbasi³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Along with graft vasculopathy, malignancies comprise a major complication after heart transplant, with a rate of occurrence of 39.1% in 10 years. Skin cancers and posttransplant lymphoproliferative disorder are more common in adults, whereas lymphoma is more often shown in children. A major cause of malignancies after heart transplant is the use of increased doses of prophylactics needed during immunosuppressive therapy. Data, however, are scarce regarding the association between a particular immunosuppressive drug and a posttransplant malignancy. Compared with the general population, recipients have a higher incidence of malignancies after heart transplant, with an early onset and more aggressive disease. Solid tumors known to occur in heart transplant recipients include lung cancer, bladder and prostate carcinoma, adenocarcinoma of the oral cavity, stomach cancer, and bowel cancer, although the incidence is rare. The risk factors for development of a malignancy after heart transplant are the same as for the nontransplant population.

show abstract

Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation

Cited by 34 publications

References 11 publications

384 Pre-Transplant Malignancy: An Analysis of Outcomes after Thoracic Organ Transplantation

384 Pre-Transplant Malignancy: An Analysis of Outcomes after Thoracic Organ Transplantation

Die Herztransplantation in der Schweiz 1969-2003

Untitled

Contact Info

Product

Resources

About